CE/CME

Allergic Rhinitis & Immunotherapy: Hope or Hype

Author and Disclosure Information

 

References

CONCLUSION
For most patients, AR has little morbidity; however, for some whose rhinitis is moderate to severe, the complications can be a concern. If symptoms are not controlled with avoidance and/or medication, AI may be indicated. It comprises the building up of tolerance to the specific allergens as identified by allergy skin testing or in vitro specific IgE testing. AI, whether SCIT or SLIT, is the only means of altering the abnormal immune system response that underlies AR. Treatment may last as long as three to four years, which provides long-term efficacy of at least three years after cessation of therapy. The long-term prognosis for AR is excellent.

Appreciation is extended to Roxy Irestone, RN, Arizona Asthma & Allergy Institute, for her assistance is gathering factual information for this article.

Pages

Recommended Reading

Hypothermia Could Prove Harmful in Adults with Severe Meningitis
Clinician Reviews
Consider MRSA in Skin and Soft Tissue Infections
Clinician Reviews
Meningococcal Vaccine for At-risk Infants
Clinician Reviews
Shingles Vaccine Most Effective When Given to Patients in Their 60s
Clinician Reviews
HPV Vaccine Uptake Low in Autoimmune Disease Patients
Clinician Reviews
Single Dose of HPV16/18 Vaccine Appears Immunogenic
Clinician Reviews
How to Manage Anemia From HCV Treatment
Clinician Reviews
Drug Combo Effective in Resistant Hepatitis C
Clinician Reviews
Clinician Recommendation Key to HPV Vaccine Coverage
Clinician Reviews
The Art and Science of Detecting Allergic Contact Dermatitis
Clinician Reviews